New Roles in Infectious Process for Molecule That Inhibits Flu Nov. 14, 2024 — Researchers have identified new roles for a protein long known to protect against severe flu infection -- among ...
Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent ...
12d
Eradivir is a Purdue Strategic Ventures portfolio company. Eradivir’s goal is to focus the power of the immune system to treat disease. The company is developing the BAiT platform (Bispecific ...
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...
The viral respiratory disease program includes two novel, Phase 1, potentially best-in-class, small molecule drug candidates: tivoxavir marboxil, in development for bird flu and seasonal influenza, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback